Clinical Trials Logo

MEK1 Gene Mutation clinical trials

View clinical trials related to MEK1 Gene Mutation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05054374 Completed - Breast Cancer Clinical Trials

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Start date: September 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations. Researchers will look at whether mirdametinib on its own or in combination with the drug fulvestrant is a safe treatment that causes few or mild side effects in people with advanced solid tumor cancer.